Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Medical Products	3.77B	3.60B	3.53B	3.43B	2.91B
Total	3.77B	3.60B	3.53B	3.43B	2.91B

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Mainland China	3.44B	3.40B	3.40B	3.36B	-
Other Countries and Regions	329.26M	202.96M	129.94M	64.97M	48.73M
China	-	-	-	-	2.73B
Total	3.77B	3.60B	3.53B	3.43B	2.78B

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 13, 2026

Data Sources Report a data error